Taprenepag isopropyl 是一个具有高度选择性的 EP₂ 受体激动剂。

Taprenepag isopropyl is a highly selective EP 2 receptor agonist.

Solid

EP2 receptor

Taprenepag isopropyl is a highly selective EP 2 receptor agonist. Intraocular pressure (IOP) in the left, vehicle-dosed eye typically remains within the normal range. In the right (Taprenepag isopropyl-dosed) eye, IOP is reduced in all dose groups. In the high-dose group, IOP is reduced to the extent that it cannot be measured (<4mm Hg) on Days 22 and 29. There are no clinical signs or changes in body weight observed with any dose of Taprenepag isopropyl administration, and no ocular findings occur for animals in the low-dose group (0.75 mg/day). has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Yanochko GM, et al. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J Ocul Pharmacol Ther. 2014 Jun;30(5):429-39.

In Vitro: DMSO : 200 mg/mL (384.17 mM; Need ultrasonic)配制储备液